Pacira BioSciences Inc

PCRX

Equity

ISIN null / Valor 12338490

NASDAQ (2025-11-14)

USD 23.78+0.68%

Pacira BioSciences Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Pacira BioSciences Inc is a pharmaceutical company that specializes in developing innovative drug delivery technologies for pain management. Their flagship product, ZILRETTA®, is the first and only approved treatment for osteoarthritis knee pain utilizing extended-release microsphere technology. In addition, the company also offers the iovera° system, an FDA-approved handheld cryoanalgesia device that delivers precise doses of cold temperature to targeted nerves, providing immediate pain relief that can last for up to three months. Pacira BioSciences Inc's proprietary multivesicular liposome (pMVL) technology allows for the encapsulation of drugs without altering their molecular structure, ensuring effective and long-lasting pain management solutions for patients.

Summarized from source with an LLMView SourceSector: Healthcare

Total Revenue

Pacira achieved total revenues of $168.9 million in Q1 2025, a slight increase from $167.1 million in the first quarter of 2024.

Net Income

The company reported a GAAP net income of $4.8 million, or $0.10 per share, compared to $9.0 million, or $0.19 per share, in Q1 2024.

Product Sales Growth

EXPAREL net sales rose to $136.5 million in Q1 2025 from $132.4 million in the previous year, while iovera° sales increased to $5.1 million compared to $5.0 million in Q1 2024.

Operational Expenses

Total operating expenses grew to $166.9 million in Q1 2025, up from $153.9 million in Q1 2024, driven by higher research and development and selling, general, and administrative costs.

Strategic Initiatives

The successful settlement of EXPAREL patent litigation and the initiation of the Phase 2 ASCEND study for PCRX-201 underscore Pacira's commitment to innovation and long-term growth.

Financial Guidance

Pacira reiterated its full-year 2025 financial guidance, projecting total revenues between $725 million and $765 million, and continues to focus on its 5x30 growth strategy.

Summarized from source with an LLMView Source

Key figures

45.3%1Y

-53.4%3Y

-62.6%5Y

Performance

43.5%1Y

56.5%3Y

49.9%5Y

Volatility